Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SARS-CoV-2 DNA Vaccine (ICCOV) in Healthy Adults
NCT05102643Phase 1Unknown
- Sponsor
- The University of Hong Kong
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ICCOV in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The University of Hong Kong. Primary endpoints: Reactogenicity and Adverse Events. Status: unknown.
02
Drugs
ICCOV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05102643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102643.